Get started
SHANGHAI FOSUN PHARMACEUTICAL (GROUP)SHANGHAI FOSUN PHARMACEUTICAL (GROUP)SHANGHAI FOSUN PHARMACEUTICAL (GROUP)

SHANGHAI FOSUN PHARMACEUTICAL (GROUP)

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

600196 chart

Key stats

Market capitalization
‪54.24 B‬CNY
Dividend yield (indicated)
1.19%
Price to earnings Ratio (TTM)
25.45
Basic EPS (TTM)
0.89CNY
Net income
‪2.39 B‬CNY
Revenue
‪41.13 B‬CNY
Shares float
‪1.17 B‬
Beta (1Y)
1.18

About SHANGHAI FOSUN PHARMACEUTICAL (GROUP)

Sector
Health Technology
CEO
De Yong Wen
Headquarters
Shanghai
Website
fosunpharma.com
Employees (FY)
‪40.37 K‬
Founded
1994
ISIN
CNE000000X38
FIGI
BBG000C4SRF1
Shanghai Fosun Pharmaceutical Group Co., Ltd. engages in the development, manufacture and sale of pharmaceutical products and medical equipment, import and export of medical equipment, healthcare services, and the provision of related and other consulting services and investment management. It operates through the following business segment: Pharmaceutical Manufacturing and R&D; Healthcare Service; Medical Devices and Medical Diagnosis; Pharmaceutical Distribution and Retail; and Other Business Operations. The Pharmaceutical Manufacturing and R&D segment involves in the production, sale, and research of medicine. The Healthcare Service segment provides healthcare service and hospital management. The Medical Devices and Medical Diagnosis segment focuses on the production and sale of medical equipment and diagnostic products. The Pharmaceutical Distribution and Retail segment issue retail and wholesale of medicine. The Other Business Operations segment comprises business that is different from the role of other segments. The company was founded on January 14, 1994 and is headquartered in Shanghai, China.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 600196 is 22.88 CNY — it has increased by 0.66% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on SSE exchange SHANGHAI FOSUN PHARMACEUTICAL (GROUP) stocks are traded under the ticker 600196.
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) is going to release the next earnings report on Apr 30, 2024. Keep track of upcoming events with our Earnings Calendar.
600196 stock is 2.08% volatile and has beta coefficient of 1.18. Check out the list of the most volatile stocks — is SHANGHAI FOSUN PHARMACEUTICAL (GROUP) there?
600196 earnings for the last quarter are 0.19 CNY per share, whereas the estimation was 0.39 CNY resulting in a −51.28% surprise. The estimated earnings for the next quarter are 0.41 CNY per share. See more details about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) earnings.
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) revenue for the last quarter amounts to ‪9.30 B‬ CNY despite the estimated figure of ‪10.61 B‬ CNY. In the next quarter revenue is expected to reach ‪9.73 B‬ CNY.
Yes, you can track SHANGHAI FOSUN PHARMACEUTICAL (GROUP) financials in yearly and quarterly reports right on TradingView.
600196 stock has risen by 0.44% compared to the previous week, the month change is a 3.05% fall, over the last year SHANGHAI FOSUN PHARMACEUTICAL (GROUP) has showed a 26.12% decrease.
600196 net income for the last quarter is ‪103.20 M‬ CNY, while the quarter before that showed ‪505.59 M‬ CNY of net income which accounts for −79.59% change. Track more SHANGHAI FOSUN PHARMACEUTICAL (GROUP) financial stats to get the full picture.
Today SHANGHAI FOSUN PHARMACEUTICAL (GROUP) has the market capitalization of ‪60.70 B‬, it has increased by 2.01% over the last week.
Yes, 600196 dividends are paid annually. The last dividend per share was 0.42 CNY. As of today, Dividend Yield (TTM)% is 1.85%. Tracking SHANGHAI FOSUN PHARMACEUTICAL (GROUP) dividends might help you take more informed decisions.
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) dividend yield was 0.98% in 2023, and payout ratio reached 27.35%. The year before the numbers were 1.12% and 27.64% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 600196 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SHANGHAI FOSUN PHARMACEUTICAL (GROUP) stock right from TradingView charts — choose your broker and connect to your account.
600196 reached its all-time high on Aug 5, 2021 with the price of 91.69 CNY, and its all-time low was 2.13 CNY and was reached on Apr 26, 2006.
See other stocks reaching their highest and lowest prices.
As of Apr 25, 2024, the company has ‪40.37 K‬ employees. See our rating of the largest employees — is SHANGHAI FOSUN PHARMACEUTICAL (GROUP) on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So SHANGHAI FOSUN PHARMACEUTICAL (GROUP) technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating SHANGHAI FOSUN PHARMACEUTICAL (GROUP) stock shows the sell signal. See more of SHANGHAI FOSUN PHARMACEUTICAL (GROUP) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) future price: according to them, 600196 price has a max estimate of 35.00 CNY and a min estimate of 24.50 CNY. Read a more detailed SHANGHAI FOSUN PHARMACEUTICAL (GROUP) forecast: see what analysts think of SHANGHAI FOSUN PHARMACEUTICAL (GROUP) and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SHANGHAI FOSUN PHARMACEUTICAL (GROUP) EBITDA is ‪3.87 B‬ CNY, and current EBITDA margin is 9.64%. See more stats in SHANGHAI FOSUN PHARMACEUTICAL (GROUP) financial statements.